

## **Technology Advisory Interests Register**

Topic: fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

**Publication Date: TBC** 

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	TAC Committee Member	Direct- financial	Michael has participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: Prostate Cancer, and in an advisory board for Accord (possible comparator company) in an unrelated disease area: Small Cell Lung Cancer	06/02/2025	It was agreed that Michael's declaration would not prevent them from participating in discussions on this appraisal.
Pedro Saramango Goncalves	TAC Committee Member	Indirect - Professional	Pedro would like to declare that he has done some health economics work in an advisory capacity for accord healthcare on an unrelated disease area (lung). And that he is part of the University of York EAG but has not participated in any capacity on the review of the evidence being presented.	06/02/2025	It was agreed that Pedro's declaration would not prevent them from participating in discussions on this appraisal.
Kate Ren	TAC Committee Member	Direct- financial	Kate provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area	06/02/2025	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			(Tofacitinib for Moderate-to-Severe Ulcerative Colitis).		
Elizabeth Thurgar	TAC Committee Member	Direct- financial	Elizabeth is currently working with Pfizer, in unrelated indication, NSCLC.	07/02/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal.
Prithwiraj Das	TAC Committee Member	Indirect - Professional	Prithwiraj is currently consulting to one of the listed competitors, GSK, in an unrelated therapy area.	20/02/2025	It was agreed that Prithwiraj's declaration would not prevent them from participating in discussions on this appraisal.
Mark Corbett	TAC Committee Member	Direct - Professional	Mark is part of the EAG team for ID5071.	10/02/2025	It was agreed that Mark's declaration would prevent them from participating in discussions as a committee member on this appraisal.